Passage BIO, Inc. 8-K — AI Bull & Bear Analysis

Passage Bio's latest 8-K reveals a decisive shift toward a remote-first, lean operating model, though it comes at a tangible cost. The company is trading long-term strategic partnerships and physical infrastructure for a more sustainable burn rate. While the move to eliminate future occupancy costs and narrow its research focus is a prudent financial step, the loss of the Gemma collaboration creates a void in its preclinical capabilities that may challenge the speed of its pipeline advancement.